193 related articles for article (PubMed ID: 34304052)
1. Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF
Mauclet C; Collard P; Ghaye B; Hoton D; Nana FA
Lung Cancer; 2021 Sep; 159():42-44. PubMed ID: 34304052
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib and Trametinib in Patients With
Luo J; Makhnin A; Tobi Y; Ahn L; Hayes SA; Iqbal A; Ng K; Arcila ME; Riely GJ; Kris MG; Yu HA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250388
[TBL] [Abstract][Full Text] [Related]
3. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.
Chimbangu CT; Ya Z; Xi L; Jiayue Z; Xiao M; Ying W; Xingxu Y; Liu X
Anticancer Drugs; 2024 Jan; 35(1):109-115. PubMed ID: 37578745
[TBL] [Abstract][Full Text] [Related]
4. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Vojnic M; Kubota D; Kurzatkowski C; Offin M; Suzawa K; Benayed R; Schoenfeld AJ; Plodkowski AJ; Poirier JT; Rudin CM; Kris MG; Rosen NX; Yu HA; Riely GJ; Arcila ME; Somwar R; Ladanyi M
J Thorac Oncol; 2019 May; 14(5):802-815. PubMed ID: 30831205
[TBL] [Abstract][Full Text] [Related]
5. Lung Cancer Driven by BRAF
Huo KG; Notsuda H; Fang Z; Liu NF; Gebregiworgis T; Li Q; Pham NA; Li M; Liu N; Shepherd FA; Marshall CB; Ikura M; Moghal N; Tsao MS
J Thorac Oncol; 2022 Feb; 17(2):277-288. PubMed ID: 34648945
[TBL] [Abstract][Full Text] [Related]
6. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
Li S; Lin X; Sun S; Li S; Zhou C
Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
[TBL] [Abstract][Full Text] [Related]
7. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
[TBL] [Abstract][Full Text] [Related]
8. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
9. Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy.
Huang Y; Gan J; Guo K; Deng Y; Fang W
J Thorac Oncol; 2019 Oct; 14(10):e236-e237. PubMed ID: 31558239
[No Abstract] [Full Text] [Related]
10. Targeting
Aboubakar Nana F; Ocak S
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
[TBL] [Abstract][Full Text] [Related]
11. [Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK].
Messekher M; François H; Denis MG; Ferrer-Lopez P; Bost-Bezeaud F; Mazières J; Parrat E
Rev Mal Respir; 2024 Jun; 41(6):451-454. PubMed ID: 38796386
[TBL] [Abstract][Full Text] [Related]
12. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
[TBL] [Abstract][Full Text] [Related]
13. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
Xie Z; Gu Y; Xie X; Lin X; Ouyang M; Qin Y; Zhang J; Lizaso A; Chen S; Zhou C
Clin Lung Cancer; 2021 May; 22(3):e390-e394. PubMed ID: 32693944
[No Abstract] [Full Text] [Related]
14. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions.
Sun M; Wang X; Xu Y; Sun C; Guo Y; Qiu S; Zhao R; Zhu W; Ma K
Thorac Cancer; 2022 Feb; 13(3):514-516. PubMed ID: 34962076
[TBL] [Abstract][Full Text] [Related]
16. An amino-terminal
Tung JK; Neishaboori N; Haraldsdottir S; Suarez CJ
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32669268
[TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
18. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
Liu Y; Zeng H; Wang K; Li Y; Tian P; Li W
Lung Cancer; 2020 Aug; 146():355-357. PubMed ID: 32553555
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
20. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.
Dagogo-Jack I; Piotrowska Z; Cobb R; Banwait M; Lennerz JK; Hata AN; Digumarthy SR; Sequist LV
J Thorac Oncol; 2019 Oct; 14(10):e226-e228. PubMed ID: 31558234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
